Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Christos Vaklavas"'
Autor:
Erica M. Stringer-Reasor, Jori E. May, Eva Olariu, Valerie Caterinicchia, Yufeng Li, Dongquan Chen, Deborah L. Della Manna, Gabrielle B. Rocque, Christos Vaklavas, Carla I. Falkson, Lisle M. Nabell, Edward P. Acosta, Andres Forero-Torres, Eddy S. Yang
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-12 (2021)
Abstract Background Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of tri
Externí odkaz:
https://doaj.org/article/73538d58c45c449bae948e795b13f120
Autor:
Edward P. Acosta, Jori E. May, Lisle Nabell, Eva Olariu, Andres Forero-Torres, Erica Stringer-Reasor, Dongquan Chen, Eddy S. Yang, Valerie Caterinicchia, Gabrielle B. Rocque, Carla I. Falkson, Christos Vaklavas, Deborah L. Della Manna, Yufeng Li
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-12 (2021)
Breast Cancer Research : BCR
Breast Cancer Research : BCR
Background Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple-negat
Autor:
Eddy S. Yang, Carla I. Falkson, Edward P. Acosta, Lisle Nabell, Jori E. May, Christos Vaklavas, Eva Olariu, Erica Stringer-Reasor, Deborah L. Della Manna, Yufeng Li, Valeria Caterinicchia, Gabrielle B. Rocque, Andres Forero-Torres
Publikováno v:
Cancer Research. 81:PS10-30
Purpose: Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2(gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple negative
Autor:
Ward Jh, Randy L. Jensen, Ling Zhao, Greenland Ja, Maihi Fujita, Rosenthal R, Saundra S. Buys, Anna C. Beck, Guoying Wang, Wadsworth Me, Emilio Cortes-Sanchez, Sandra D. Scherer, Chieh-Hsiang Yang, Katrin P. Guillen, Jeffrey H. Chuang, Cindy B. Matsen, Zheqi Li, Kristopher Berrett, Jeffery M. Vahrenkamp, David H. Lum, Alana L. Welm, Michael T. Lewis, Toner J, Jason Gertz, Chu Z, Poretta Jm, Yoko S. DeRose, Lacey E. Dobrolecki, Gabor T. Marth, Katherine E. Varley, Rachel E. Factor, Andrew Butterfield, Bryan E. Welm, Xiaomeng Huang, Edward W. Nelson, Matthew H. Bailey, Pathi Ss, Xing Yi Woo, Yi Qiao, Christos Vaklavas, Steffi Oesterreich, Kevin B. Jones
Model systems that recapitulate the complexity of human tumors and the reality of variable treatment responses are urgently needed to better understand cancer biology and to develop more effective cancer therapies. Here we report development and char
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb9f2dc64567b20d35abfdfca6812bd3
https://doi.org/10.1101/2021.02.28.433268
https://doi.org/10.1101/2021.02.28.433268
Autor:
Antonio C. Wolff, Nan Lin, Julie R. Nangia, William J. Irvin, Rita Nanda, Dafydd G. Thomas, Catherine Van Poznak, Minetta C. Liu, Kimberly Aung, Kelley M. Kidwell, Christos Vaklavas, Tiffany A. Traina, Martha E. Brown, Anna Maria Storniolo, Daniel F. Hayes, Costanza Paoletti, Andres Forero-Torres, Vandana G. Abramson, Maria C. Muñiz, Yufeng Li
Publikováno v:
Clinical Cancer Research. 21:2771-2779
Purpose: Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). We tested whether EpCAM-based capture system (CellSearch) is effective in patients with triple-negative (TN) MBC, and whether CTC apoptosis and clustering enhanc
Autor:
Rita Nanda, Dafydd G. Thomas, William J. Irvin, Julie R. Nangia, Martha E. Brown, MC Liu, Andres Forero, Maria C. Muñiz, TA Traina, Kimberly Aung, Yufeng Li, Vandana G. Abramson, Kelley M. Kidwell, Nu Lin, Costanza Paoletti, Daniel F. Hayes, Antonio C. Wolff, Anna Maria Storniolo, C. Van Poznak, Christos Vaklavas
Publikováno v:
Cancer Research. 73:P1-04
Background: Circulating Tumor cells (CTCs) are prognostic at baseline and first follow-up in patients with metastatic breast cancer (MBC). Using the most commonly used assay (CellSearch®), we have previously reported the ability to detect apoptotic
Autor:
Kurt R. Zinn, Kedar Shrestha, Christos Vaklavas, William E. Grizzle, Zheng Meng, Scott W. Blume, Hyoungsoo Choi
Publikováno v:
Tumour Biology
Internal ribosome entry site (IRES)-mediated translation is a specialized mode of protein synthesis which malignant cells depend on to survive adverse microenvironmental conditions. Our lab recently reported the identification of a group of compounds
Publikováno v:
Current Treatment Options in Oncology. 12:369-388
Over the recent years, there has been an increasing recognition that triple-negative breast cancer constitutes a separate, albeit heterogeneous, entity arising from distinct oncogenic pathways. Despite its aggressive clinical behavior, triple-negativ
Autor:
Kurt R. Zinn, Hyoungsoo Choi, William E. Grizzle, Scott W. Blume, Christos Vaklavas, Zheng Meng
Publikováno v:
Cancer Biology & Therapy
Many genes controlling cell proliferation and survival (those most important to cancer biology) are now known to be regulated specifically at the translational (RNA to protein) level. The internal ribosome entry site (IRES) provides a mechanism by wh
Publikováno v:
Antibody-Drug Conjugates and Immunotoxins ISBN: 9781461454557
The development of monoclonal antibodies as cancer therapeutic agents has improved the outlook for many patients as evidenced by the number of such drugs that have been approved for oncologic indications [1]. Monoclonal antibodies allow selective kil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75d8472c8fa323447fc7bedff9c3f44e
https://doi.org/10.1007/978-1-4614-5456-4_12
https://doi.org/10.1007/978-1-4614-5456-4_12